⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
XENE News
Xenon Pharmaceuticals Inc
NYU Langone Health Neurologists Present Latest Clinical Findings and Research at AAN 2026
prnewswire.com
XENE
Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting
globenewswire.com
XENE
Xenon to Present at Upcoming Investor Conferences
globenewswire.com
XENE
Form 8-K
sec.gov
XENE
Xenon to Highlight Phase 3 X-TOLE2 & Long-Term Data for Azetukalner in Focal Onset Seizures at 2026 AAN Annual Meeting
globenewswire.com
XENE
Form 8-K
sec.gov
XENE
Form 8-K
sec.gov
XENE
Xenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
globenewswire.com
XENE
Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering
globenewswire.com
XENE
Xenon Pharmaceuticals Announces Proposed Public Offering
globenewswire.com
XENE